The role of MZT2A in skin cutaneous melanoma based on multiomics data
10.3969/j.issn.1673-9701.2025.06.003
- VernacularTitle:多组学分析MZT2A在皮肤黑色素瘤中的作用
- Author:
Ziqian XU
1
;
Bingjiang LIN
;
Xie QIU
;
Hua HUANG
;
Suling XU
;
Lingyi LU
Author Information
1. 宁波大学附属第一医院皮肤科,浙江宁波 315010
- Publication Type:Journal Article
- Keywords:
Skin cutaneous melanoma;
Mitotic spindle organizing protein 2A;
Prognosis;
Multiomics;
Immunotherapy
- From:
China Modern Doctor
2025;63(6):11-18
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore and evaluate the association between mitotic spindle organizing protein 2A(MZT2A)and survival prognosis and immunotherapy response of skin cutaneous melanoma(SKCM),based on multiomics data mining.Methods The expression difference and survival prognosis of MZT2A in SKCM were analyzed by the Cancer Genome Atlas database,Genotype-tissue Expression Data,Human Protein Atlas,SUMMER database.The biological function of MZT2A and related enriched pathways were analyzed by David2.The differences of immune infiltrating cells,immune therapy response and immune escape ability between high-and low-MZT2A groups were analyzed and compared by using Tumor Immune Estimation Resource,Tumor Immune Single-cell Hub,Tumor-immune System Interactions database,the Cancer Imaging Archive and Tumor Immune Dysfunction and Exclusion databases.Results The expression of MZT2A gene elevated in a variety of cancers,especially in SKCM.SKCM samples with high expression of MZT2A had a poor overall survival.The expression of MZT2A was negatively correlated with the infiltration of CD8+T cells,CD4+T cells,macrophages,neutrophils and dendritic cells in SKCM tissues.In addition,the higher the expression of MZT2A,the therapeutic response of SKCM were worse to immune checkpoint inhibitors(ICI).Conclusion MZT2A is a novel survival prediction target of SKCM.SKCM patients with high expression of MZT2A have poor response to ICI treatment,which provides a theoretical basis for predicting the survival prognosis and guiding immune targeted therapy of SKCM.
